Lisata Therapeutics (LSTA) 10-Q 8 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information Document (USD $)	3 Months Ended
	Mar. 31, 2014	8-May-14	Jun. 30, 2013
Document Information [Line Items]	'	'	'
Entity Registrant Name	'NeoStem, Inc.	'	'
Entity Central Index Key	'0000320017	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Accelerated Filer	'	'
Document Type	'10-Q	'	'
Document Period End Date	31-Mar-14	'	'
Document Fiscal Year Focus	'2014	'	'
Document Fiscal Period Focus	'Q1	'	'
Amendment Flag	'false	'	'
Entity Common Stock, Shares Outstanding	'	34,008,862	'
Entity Public Float	'	'	$92,300,000

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current Assets	'	'
Cash and cash equivalents	$41,359,652	$46,133,759
Accounts receivable, net of allowance for doubtful accounts of $390,118 and $391,829 at March 31, 2014 and December 31, 2013, respectively	1,887,558	1,860,835
Inventory	1,475,812	1,270,223
Prepaid expenses and other current assets	1,833,082	1,561,933
Total current assets	46,556,104	50,826,750
Property, plant and equipment, net	13,790,672	12,844,216
Goodwill	11,117,770	11,117,770
Intangible assets, net	13,724,314	13,875,617
Other assets	1,204,765	1,151,729
Assets, Total	86,393,625	89,816,082
Current Liabilities	'	'
Accounts payable	3,296,078	3,354,908
Accrued liabilities	2,381,625	4,018,026
Notes payable	836,219	381,097
Mortgages payable	216,005	213,112
Derivative Liabilities, Current	23,175	23,175
Unearned revenues	2,033,116	1,816,601
Total current liabilities	8,786,218	9,806,919
Long-term Liabilities	'	'
Deferred income taxes	4,426,635	4,379,226
Notes payable	870,864	531,164
Secured Long-term Debt, Noncurrent	2,967,948	3,023,609
Business Combination, Contingent Consideration, Liability	9,640,000	9,450,000
Other long-term liabilities	635,008	598,729
Total liabilities	27,326,673	27,789,647
Commitments and Contingencies	'	'
Stockholders' Equity	'	'
Preferred stock, authorized, 20,000,000 shares; Series B convertible redeemable preferred stock liquidation value, 1/100 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at March 31, 2014 and December 31, 2013	100	100
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 28,593,410 and 27,196,537 shares, at March 31, 2014 and December 31, 2013, respectively	28,594	27,197
Additional paid-in capital	310,377,112	299,594,525
Treasury stock, at cost	-705,742	-705,742
Accumulated deficit	-250,055,662	-236,373,605
Total NeoStem, Inc. stockholders' equity	59,644,402	62,542,475
Noncontrolling interests	-577,450	-516,040
Total equity	59,066,952	62,026,435
Liabilities and Equity, Total	$86,393,625	$89,816,082

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Preferred Stock, Shares Outstanding	10,000	10,000
Common Stock, Par Value	$0.00	$0.00
Accounts receivable trade, net of allowance for doubtful accounts	$390,118	$391,829
Preferred Stock, authorized	20,000,000	20,000,000
Common stock, outstanding	28,593,410	27,196,537
Common Stock, authorized	500,000,000	500,000,000
Common Stock, Shares, Issued	28,593,410	27,196,537
Preferred stock, shares designated	825,000	825,000
Preferred stock, issued	10,000	10,000
Preferred stock, Series B convertible redeemable preferred stock liquidation value, share of common stock	1	1
Preferred stock, par value	$0.01	$0.01

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Revenues	$4,055,575	$2,523,912
Cost of revenues	3,825,444	2,392,089
Research and development	4,759,083	3,161,326
Selling, general, and administrative	8,970,016	5,801,872
Total operating costs and expenses	17,554,543	11,355,287
Operating loss	-13,498,968	-8,831,375
Other income (expense):	'	'
Other income (expense), net	-189,551	10,606
Interest expense	-94,156	-43,560
Nonoperating Income (Expense), Total	-283,707	-32,954
Loss before provision for income taxes and noncontrolling interests	-13,782,675	-8,864,329
Provision for income taxes	47,409	0
Net loss	-13,830,084	-8,864,329
Less - loss attributable to noncontrolling interests	-148,027	-63,754
Net Income (Loss) Available to Common Stockholders, Basic	-13,682,057	-8,800,575
Amounts Attributable to NeoStem, Inc. common stockholders:	'	'
Net Income (Loss) Available to Common Stockholders, Basic	($13,682,057)	($8,800,575)
NeoStem, Inc. common stockholders	($0.49)	($0.53)
Weighted average common shares outstanding	28,120,847	16,698,897

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Net loss	($13,830,084)	($8,864,329)
Total other comprehensive (loss) income	0	0
Comprehensive loss	-13,830,084	-8,864,329
Comprehensive loss attributable to noncontrolling interests	-148,027	-63,754
Comprehensive net loss attributable to NeoStem, Inc. common stockholders	($13,682,057)	($8,800,575)

Consolidated_Statements_of_Equ

Consolidated Statements of Equity (USD $)	Total	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]	Total NeoStem, Inc. Shareholders' Equity [Member]	Noncontrolling Interest [Member]
Beginning Balance at Dec. 31, 2012	$32,820,159	$100	$16,375	$231,218,615	$0	($197,392,361)	($665,600)	$33,177,129	($356,970)
Beginning Balance (shares) at Dec. 31, 2012	'	10,000	16,375,365	'	'	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'	'	'	'
Net loss	-8,864,329	'	'	'	'	-8,800,575	'	-8,800,575	-63,754
Share-based compensation (in shares)	'	'	177,492	'	'	'	'	'	'
Share-based compensation	2,218,530	'	178	2,218,352	'	'	'	2,218,530	'
Net proceeds from issuance of common stock (in shares)	'	'	454,254	'	'	'	'	'	'
Net proceeds from issuance of common stock	2,730,263	'	455	2,729,808	'	'	'	2,730,263	'
Proceeds from Stock Options Exercised	0	'	'	'	'	'	'	'	'
Proceeds from warrant exercise (in shares)	'	'	20,761	'	'	'	'	'	'
Proceeds from exercise of warrants	105,881	'	21	105,860	'	'	'	105,881	'
Warrant Inducements (in shares)	'	'	0	'	'	'	'	'	'
Warrant Inducements	'	'	0	-6,239	'	'	'	-6,239	'
Adjustments to Additional Paid in Capital, Warrant Issued	-6,239	'	'	'	'	'	'	'	'
Ending Balance at Mar. 31, 2013	29,004,265	100	17,029	236,266,396	0	-206,192,936	-665,600	29,424,989	-420,724
Ending Balance (shares) at Mar. 31, 2013	'	10,000	17,027,872	'	'	'	'	'	'
Beginning Balance at Dec. 31, 2013	62,026,435	100	27,197	299,594,525	0	-236,373,605	-705,742	62,542,475	-516,040
Beginning Balance (shares) at Dec. 31, 2013	'	10,000	27,196,537	'	'	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'	'	'	'
Net loss	-13,830,084	'	'	'	'	-13,682,057	'	-13,682,057	-148,027
Share-based compensation (in shares)	'	'	329,698	'	'	'	'	'	'
Share-based compensation	3,893,616	'	330	3,893,286	'	'	0	3,893,616	'
Net proceeds from issuance of common stock (in shares)	'	'	804,375	'	'	'	'	'	'
Net proceeds from issuance of common stock	5,630,625	'	804	5,629,821	'	'	'	5,630,625	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	'	'	12,800	'	'	'	'	'	'
Proceeds from Stock Options Exercised	71,360	'	13	71,347	'	'	'	71,360	'
Proceeds from warrant exercise (in shares)	'	'	250,000	'	'	'	'	'	'
Proceeds from exercise of warrants	1,275,000	'	250	1,274,750	'	'	'	1,275,000	'
Change in Ownership in Subsidiary	0	'	0	-86,617	'	'	'	-86,617	86,617
Ending Balance at Mar. 31, 2014	$59,066,952	$100	$28,594	$310,377,112	$0	($250,055,662)	($705,742)	$59,644,402	($577,450)
Ending Balance (shares) at Mar. 31, 2014	'	10,000	28,593,410	'	'	'	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Net loss	($13,830,084)	($8,864,329)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Equity-based compensation expense	3,893,616	2,218,530
Depreciation and amortization	444,452	554,954
Changes in fair value of derivative liability	0	10,606
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	190,000	0
Bad debt recovery	-1,711	0
Deferred Income Taxes	47,409	0
Prepaid expenses and other current assets	-271,149	-192,009
Accounts receivable	-25,012	167,444
Inventory	-205,589	-428,549
Unearned revenues	216,515	346,912
Other assets	-53,035	-22,986
Accounts payable, accrued expenses and other liabilities	-1,658,952	-905,094
Net cash used in operating activities	-11,253,540	-7,135,733
Cash flows from investing activities:	'	'
Acquisition of property and equipment	-1,239,606	-53,571
Net cash used in investing activities	-1,239,606	-53,571
Cash flows from financing activities:	'	'
Proceeds from Stock Options Exercised	71,360	0
Proceeds from exercise of warrants	1,275,000	105,881
Net proceeds from issuance of common stock	5,630,625	2,730,262
Repayment of mortgage loan	-52,768	-43,446
Proceeds from notes payable	958,014	0
Repayment of notes payable	-163,192	-81,015
Change in warrant liabilities	0	-6,239
Net cash provided by financing activities	7,719,039	2,705,443
Net decrease in cash and cash equivalents	-4,774,107	-4,483,861
Cash and cash equivalents at beginning of period	46,133,759	13,737,452
Cash and cash equivalents at end of period	41,359,652	9,253,591
Cash and cash equivalents of continuing operations at end of period	41,359,652	'
Supplemental Disclosure of Cash Flow Information:	'	'
Interest	93,100	95,700
Taxes	$0	$0

The_Business

The Business	3 Months Ended
	Mar. 31, 2014
The Business [Abstract]	'
Nature of Operations [Text Block]	'
	The Business
	Overview
	NeoStem, Inc. (“we,” “NeoStem” or the “Company”) is a leader in the emerging cellular therapy industry. We are pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease. We have multiple cell therapy platforms that work to address the pathology of disease using a person's own cells to amplify the body's natural repair mechanisms including enhancing the destruction of cancer initiating cells, repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that cell therapy will play a large role in changing the natural history of diseases as more breakthrough therapies are developed, ultimately lessening the overall burden of disease on patients and their families as well as the economic burden that these diseases impose upon modern society.
	Our business includes the development of novel proprietary cell therapy products, as well as a revenue-generating contract development and manufacturing service business that we leverage for the development of our therapeutics while providing service to other companies in the cell therapy industry developing products. The combination of our own therapeutic development business and a revenue-generating service provider business provides the Company with unique capabilities for cost effective in-house product development and immediate revenue and future cash flow to help underwrite our internal development programs. This business model enables the Company to be opportunistic in growing its pipeline as evidenced by the Company's acquisition in May 2014 through the issuance of equity of California Stem Cell, Inc. ("CSC"), a cell biotechnology corporation that is developing cellular immunotherapies for cancer, an area we view to be one of the most promising sub-sectors in biotechnology. CSC, now known as NeoStem Oncology, LLC, is driving the Company's Targeted Immunotherapy Program for cancer through the development of its lead product candidate, Melapuldencel-T, to treat Stage IV or recurrent melanoma. The Phase 3 protocol is the subject of a Special Protocol Assessment (SPA), indicating that the Food and Drug Administration ("FDA") is in agreement with the design, clinical endpoints, and planned clinical analyses of the Phase 3 trial that will serve as the basis for a Biologics License Application ("BLA"). This protocol calls for enrolling 250 patients and is expected to be initiated in 2014.
	We are currently developing therapies to address ischemia through our CD34 Cell Program. Ischemia occurs when the supply of oxygenated blood in the body is restricted. We seek to reverse this restriction through the development and formation of new blood vessels. AMR-001 is our most clinically advanced product candidate in our CD34 Cell Program and is being developed to treat damaged heart muscle following an acute myocardial infarction (heart attack) ("AMI"). In December 2013, the Company completed enrollment in its PreSERVE AMI study. PreSERVE AMI is a randomized, double-blinded, placebo-controlled Phase 2 clinical trial testing AMR-001, an autologous (donor and recipient are the same) adult stem cell product for the treatment of patients with left ventricular dysfunction following acute ST segment elevation myocardial infarction (STEMI). With the last patient of the planned 160 patient trial infused in late December 2013, we expect the last patient six-month follow-up to occur in June 2014. Once the primary end point six-month data is collected, the data set will be locked and analysis will begin with a submission for a possible presentation of the study at the American Heart Association's Scientific Sessions to be held November 15-19, 2014. If approved by Food and Drug Administration (the "FDA ") and/or other worldwide regulatory agencies following successful completion of further trials, AMR-001 would address a significant medical need for which there is currently no effective treatment, potentially improving longevity and quality of life for those suffering a STEMI, and positioning the Company to capture a meaningful share of this worldwide market. We also expect to advance the technology into other clinical indications such as chronic heart failure ("CHF"), traumatic brain injury ("TBI"), and/or critical limb ischemia ("CLI").
	Another platform technology we are developing utilizes T Regulatory Cells ("Tregs") to treat diseases caused by imbalances in an individual's immune system.  In collaborating with Becton-Dickinson and the University of California, San Francisco, we are utilizing this technology platform of our majority-owned subsidiary, Athelos Corporation ("Athelos"), to restore immune balance by enhancing Treg cell number and function.  Tregs are a natural part of the human immune system and regulate the activity of T effector cells, the cells that are responsible for protecting the body from viruses and  other foreign antigen exposure. When Tregs function properly, only harmful foreign materials are attacked by T effector cells. In autoimmune disease it is thought that deficient Treg activity permits the T effector cells to attack the body's own tissues, and in allergic diseases, like asthma, the immune system overreacts to harmless foreign substances. We plan to initiate a Phase 2 study of Treg based therapeutics  to treat type 1 diabetes in 2014. We also plan to initiate a Phase 1 study in Canada of Treg based therapeutics in support of a steroid resistant asthma indication in 2014.
	Pre-clinical assets include our VSEL TM (Very Small Embryonic Like) Technology regenerative medicine platform. Regenerative medicine holds the promise of improving clinical outcomes and reducing overall  healthcare costs.  We are working on a Department of Defense funded study of VSELsTM for the treatment of chronic wounds. Other preclinical work with VSELsTM includes exploring macular degeneration as a target indication.
	Progenitor Cell Therapy, LLC ("PCT") is a contract manufacturer that generates revenue. This wholly owned subsidiary, which we acquired in 2011, is an industry leader in providing high quality manufacturing capabilities and support to developers of cell-based therapies to enable them to improve efficiencies and profitability and reduce capital investment for their own development activities. Since its inception more than 15 years ago, PCT has provided pre-clinical and clinical current Good Manufacturing Practice (“cGMP”) development and manufacturing services to more than 100 clients. PCT has experience advancing regenerative medicine product candidates from product inception through rigorous quality standards all the way through to human testing, BLA filing and FDA product approval. PCT's core competencies in the cellular therapy industry include manufacturing of cell therapy-based products, engineering and innovation services, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery and consulting services. PCT has two cGMP, state-of-the art cell therapy research, development, and manufacturing facilities in New Jersey and California, serving the cell therapy community with integrated and regulatory compliant distribution capabilities. The Company is pursuing commercial expansion of our manufacturing operations both in the U.S. and internationally. Additionally, with the acquisition of CSC, PCT can leverage CSC's additional manufacturing capacity in Irvine, California as well as the personnel experience and expertise in immunotherapy to provide additional manufacturing and /or development work to advance NeoStem's platform technology as well as technologies of PCT's client base.
	Strategic acquisitions have been the cornerstone of NeoStem’s growth and have been selected in order to provide value to stockholders by taking advantage of the infrastructure we have created which includes strong development, regulatory and manufacturing expertise. By adding Melapuldencel-T, a late stage novel proprietary cancer cell therapy into our pipeline, we look to further advance towards our goal of delivering transformative cell based therapies to the market to help patients suffering from life-threatening medical conditions. Coupled with our best in class manufacturing capability, the stage is set for us to realize meaningful clinical development and manufacturing efficiencies, further positioning NeoStem to lead the cell therapy industry.
	Basis of Presentation
	The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“generally accepted accounting principles”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of March 31, 2014 and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2013 and 2012 included in our Annual Report on Form 10-K for the year ended December 31, 2013. Operating results for the three months ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014.
	Use of Estimates
	The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates.
	Reclassifications
	Certain reclassifications have been made to the Consolidated Financial Statements and Notes to the Consolidated Financial Statements for the three months ended March 31, 2013 to conform to the presentation for the three months ended March 31, 2014.
	Principles of Consolidation
	The Consolidated Financial Statements include the accounts of NeoStem, Inc. and its wholly owned and partially owned subsidiaries and affiliates as listed below.
	Entity	Percentage of Ownership	Location
	NeoStem, Inc.	Parent  Company	United States of America
	NeoStem Therapies, Inc.	100%	United States of America
	Stem Cell Technologies, Inc.	100%	United States of America
	Amorcyte, LLC	100%	United States of America
	Progenitor Cell Therapy, LLC (PCT)	100%	United States of America
	NeoStem Family Storage, LLC	100%	United States of America
	Athelos Corporation (1)	90%	United States of America
	PCT Allendale, LLC	100%	United States of America
	NeoStem Oncology, LLC (2)	100%	United States of America
	(1) Pursuant to the Stock Purchase Agreement signed in March 2011, our initial ownership in Athelos was 80.1%, and Becton Dickinson's ("BD") initial minority ownership was 19.9%. Per the Agreement, BD will be diluted based on new investment in Athelos by us (subject to certain anti-dilution provisions). As of March 31, 2014, BD's ownership interest in Athelos was decreased to 10.0%, and our ownership increased to 90.0%. As a result in the change in ownership, approximately $0.1 million was transferred from additional paid in capital to non-controlling interests.
	(2) On May 8, 2014, NeoStem acquired CSC, now known as NeoStem Oncology, LLC (see Note 15, Subsequent Events). Accordingly, the accounts of NeoStem Oncology, LLC are not included in the Company's consolidated financial position as of March 31, 2014 and the results of its consolidated operations and cash flows for the three months ended March 31, 2014 and 2013.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Summary of Significant Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies [Text Block]	'
	Summary of Significant Accounting Policies
	In addition to the policies below, our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2013. There were no changes during the three months ended March 31, 2014.
	Cash and Cash Equivalents
	Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.
	Accounts Receivable
	Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. The Company applies judgment in connection with establishing the allowance for doubtful accounts. Specifically, the Company analyzes the aging of accounts receivable balances, historical bad debts, customer concentration and credit-worthiness, current economic trends and changes in the Company’s customer payment terms. Significant changes in customer concentrations or payment terms, deterioration of customer credit-worthiness or weakening economic trends could have a significant impact on the collectability of the receivables and the Company’s operating results. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. Management regularly reviews the aging of receivables and changes in payment trends by its customers, and records a reserve when it believes collection of amounts due are at risk.
	Inventories
	The Company, through its PCT subsidiary, regularly enters into contracts with clients for services that have multiple stages and are dependent on one another to complete the contract and recognize revenue. The Company's inventory represents work in process for costs incurred on such projects at PCT that have not been completed. The Company reviews these projects periodically to determine that the value of each project is stated at the lower of cost or market.
	Goodwill and Other Intangible Assets
	Goodwill is the excess of purchase price over the fair value of identified net assets of businesses acquired. The Company’s intangible assets with an indefinite life are related to in process research and development ("IPR&D") for AMR-001, the clinical candidate acquired in the Amorcyte acquisition, as the Company expects this research and development to provide the Company with substantial benefit for a period that extends beyond the foreseeable horizon. Intangible assets with indefinite useful lives are measured at their respective fair values as of the acquisition date. The Company does not amortize goodwill and intangible assets with indefinite useful lives. Intangible assets related to IPR&D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.
	The Company reviews goodwill and indefinite-lived intangible assets at least annually for possible impairment. Goodwill and indefinite-lived intangible assets are reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. The Company tests its goodwill and indefinite-lived intangible assets each year on December 31. The Company reviews the carrying value of goodwill and indefinite-lived intangible assets utilizing a discounted cash flow model, and, where appropriate, a market value approach is also utilized to supplement the discounted cash flow model. The Company makes assumptions regarding estimated future cash flows, discount rates, long-term growth rates and market values to determine each reporting unit’s estimated fair value. If these estimates or related assumptions change in the future, the Company may be required to record impairment charges. In accordance with it's accounting policy, the Company tested goodwill and indefinite-lived intangible assets for impairment as of December 31, 2013 and 2012 for its two reporting units, and concluded there was no risk of failing step 1 of the goodwill impairment testing evaluation, and that indefinite-lived intangible assets were not impaired.
	Amortized intangible assets consist of customer lists, manufacturing technology, and tradename, as well as patents and rights associated primarily with the VSEL™ Technology. These intangible assets are amortized on a straight line basis over their respective useful lives.
	Revenue Recognition
	Clinical Services: The Company recognizes revenue for its (i) process development and (ii) clinical manufacturing services based on the terms of individual contracts.
	Revenues associated with process development services generally contain multiple stages that do not have stand-alone values and are dependent upon one another, and are recognized as revenue on a completed contract basis. We recognize revenues when all of the following conditions are met:
	•	persuasive evidence of an arrangement exists;
	•	delivery has occurred or the services have been rendered;
	•	the fee is fixed or determinable; and
	•	collectability is probable.
	The Company considers signed contracts as evidence of an arrangement. The Company assesses whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the payment terms are subject to refund or adjustment. The Company assesses cash collectability based on a number of factors, including past collection history with the client and the client's creditworthiness. If the Company determines that collectability is not reasonably assured, it defers revenue recognition until collectability becomes reasonably assured, which is generally upon receipt of the cash. The Company's arrangements are generally non-cancellable, though clients typically have the right to terminate their agreement for cause if the Company materially fails to perform.
	Clinical manufacturing services are generally distinct arrangements whereby the Company is paid for time and materials or for fixed monthly amounts. Revenue is recognized when efforts are expended or contractual terms have been met.
	Some client agreements include multiple elements, comprised of process development and clinical manufacturing services. The Company believes that process development and clinical manufacturing services each have stand-alone value because these services can be provided separately by other companies. In accordance with ASC Update No. 2009-13, “Revenue Recognition (Topic 605): Multiple-Deliverable Revenue Arrangements,” the Company (1) separates deliverables into separate units of accounting when deliverables are sold in a bundled arrangement and (2) allocates the arrangement's consideration to each unit in the arrangement based on its relative selling price.
	Clinical Services Reimbursements: The Company separately charges the customers for the expenses associated with certain consumable resources (reimbursable expenses) that are specified in each clinical services contract. On a monthly basis, the Company bills customers for reimbursable expenses and immediately recognizes these billings as revenue, as the revenue is deemed earned as reimbursable expenses are incurred. For the three months ended March 31, 2014 and 2013, clinical services reimbursements were $0.7 million and $0.4 million, respectively.
	Processing and Storage Services: The Company recognizes revenue related to the collection and cryopreservation of cord blood and autologous adult stem cells when the cryopreservation process is completed which is approximately twenty-four hours after cells have been collected. Revenue related to advance payments of storage fees is recognized ratably over the period covered by the advance payments.

Cash_and_Cash_Equivalents

Cash and Cash Equivalents	3 Months Ended
	Mar. 31, 2014
Cash and Cash Equivalents [Abstract]	'
Cash and Cash Equivalents [Text Block]	'
	Cash and Cash Equivalents
	As of March 31, 2014 and December 31, 2013, the Company had cash and cash equivalents of approximately $41.4 million and $46.1 million, respectively, including bank deposits of approximately $0.7 million and $0.8 million, respectively, covered by the Federal Deposit Insurance Corporation.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2014
Inventories [Abstract]	'
Inventory Disclosure [Text Block]	'
	Inventories
	Inventories, representing work in process for costs incurred on projects at PCT that have not been completed, were $1.5 million and $1.3 million as of March 31, 2014 and December 31, 2013, respectively. The Company also has deferred revenue of approximately $1.6 million and $1.5 million of advance billings received as of March 31, 2014 and December 31, 2013, respectively, related to these contracts.

Loss_Per_Share

Loss Per Share	3 Months Ended
	Mar. 31, 2014
Loss Per Share [Abstract]	'
Loss Per Share [Text Block]	'
	Loss Per Share
	For the three months ended March 31, 2014 and 2013, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of loss per share. At March 31, 2014 and 2013, the Company excluded the following potentially dilutive securities:
		March 31,
		2014	2013
	Stock Options	3,912,697	2,631,181
	Warrants	4,491,028	5,501,055
	Restricted Shares	175,731	35,500

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2014
Fair Value Measurements [Abstract]	'
Fair Value Disclosures [Text Block]	'
	Fair Value Measurements
	Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:
	Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
	Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.
	Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.
	The Company determined the fair value of the warrant derivative liabilities to be level 3 inputs. These inputs require material subjectivity because value is derived through the use of a lattice model that values the derivatives based on probability weighted discounted cash flows.
	Contingent consideration was recognized on October 17, 2011 in connection with the Company's acquisition of Amorcyte. The contingent consideration obligations relates to earn out payments equal to 10% of the net sales of Amorcyte’s lead product candidate AMR-001 (in the event of and following the date of first commercial sale of AMR-001), provided that in the event NeoStem sublicenses AMR-001, the applicable earn out payment will be equal to 30% of any sublicensing fees, and provided further that NeoStem will be entitled to recover direct out-of-pocket clinical development costs not previously paid or reimbursed and any costs, expenses, liabilities and settlement amounts arising out of claims of patent infringement or otherwise challenging Amorcyte’s right to use intellectual property, by reducing any earn out payments due by 50% until such costs have been recouped in full (the “Earn Out Payments”).
	The fair value of contingent consideration obligations is determined using Level 3 inputs, and is based on a discounted cash flow model using a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on our own assumptions and experience. We base the timing to complete the development and approval of this product on the current development stage of the product and the inherent difficulties and uncertainties in developing a product candidate, such as obtaining U.S. Food and Drug Administration (FDA) and other regulatory approvals. In determining the probability of regulatory approval and commercial success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period. Changes in the fair value of the contingent consideration obligations are recorded in our consolidated statement of operations. The contingent consideration fair value increased from $9.5 million as of December 31, 2013 to $9.6 million as of March 31, 2014. The change in estimated fair value is based the impact of the time progression through the Phase 2 clinical trial from December 31, 2013 to March 31, 2014.
	The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2014, and December 31, 2013 (in thousands):
		March 31, 2014
		Fair Value Measurements Using Fair Value Hierarchy
		Level 1			Level 2			Level 3
	Warrant derivative liabilities	$	—		$	—		$	23.2
	Acquisition-related contingent consideration	—			—			9,640.00
		December 31, 2013
		Fair Value Measurements Using Fair Value Hierarchy
		Level 1			Level 2			Level 3
	Warrant derivative liabilities	$	—		$	—		$	23.2
	Acquisition-related contingent consideration	—			—			9,450.00
	For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the three months ended March 31, 2014 by type of instrument (in thousands):
			Three Months Ended
			March 31, 2014
			Warrants			Acquisition-Related Contingent Consideration
	Beginning liability balance		$	23.2		$	9,450.00
	Change in fair value recorded in earnings		—			190
	Ending liability balance		$	23.2		$	9,640.00
	Some of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate fair value due to their liquid or short-term nature, such as cash and cash equivalents, accounts receivable, accounts payable. Our long-term debt and notes payable are carried at cost and approximate fair value due to their variable or fixed interest rates, which are consistent with the interest rates in the market.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	3 Months Ended
	Mar. 31, 2014
Goodwill and Other Intangible Assets [Abstract]	'
Goodwill and Intangible Assets [Text Block]	'
	Goodwill and Other Intangible Assets
	The Company's goodwill was $11.1 million as of March 31, 2014 and December 31, 2013.
	The Company's intangible assets and related accumulated amortization as of March 31, 2014 and December 31, 2013 consisted of the following (in thousands):
				31-Mar-14								31-Dec-13
		Useful Life		Gross			Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
	Customer list	10 years		$	1,000.00		$	(320.1	)	$	679.9	$	1,000.00	$	(295.1	)	$	704.9
	Manufacturing technology	10 years		3,900.00			(1,248.4		)	2,651.60		3,900.00		(1,150.9		)	2,749.10
	Tradename	10 years		800			(256.1		)	543.9		800		(236.1		)	563.9
	In process R&D	Indefinite		9,400.00			—			9,400.00		9,400.00		—			9,400.00
	VSEL patent rights	19 years		669			(220.1		)	448.9		669		(211.3		)	457.7
	Total Intangible Assets			$	15,769.00		$	(2,044.7	)	$	13,724.30	$	15,769.00	$	(1,893.4	)	$	13,875.60
	Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):
			Three Months Ended March 31,
			2014			2013
	Cost of revenue		$	79.2		$	97.5
	Research and development		27.1			8.8
	Selling, general and administrative		45			45
	Total		$	151.3		$	151.3
	Estimated intangible amortization expense on an annual basis for the succeeding five years is as follow (in thousands):
	2014	$	453.9
	2015	605.2
	2016	605.2
	2017	605.2
	2018	605.2
	Thereafter	10,849.60
		$	13,724.30

Accrued_Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2014
Accrued Liabilities [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	Accrued Liabilities
	Accrued liabilities as of March 31, 2014 and December 31, 2013 were as follows (in thousands):
		March 31, 2014		31-Dec-13
	Salaries, employee benefits and related taxes	$	846.4	$	2,325.80
	Professional fees	775.4		544.8
	License Fees	200		500
	Other	559.8		647.4
		$	2,381.60	$	4,018.00

Debt

Debt	3 Months Ended
	Mar. 31, 2014
Debt [Abstract]	'
Debt Disclosure [Text Block]	'
	Debt
	Notes Payable
	As of March 31, 2014 and December 31, 2013, the Company had notes payable of approximately $1.7 million and $0.9 million, respectively. The notes relate to certain insurance policies and equipment financings, require monthly payments, and mature within one to three years.
	Mortgages Payable
	In October 2007, PCT issued a note to borrow $3.1 million (the “First Mortgage”) in connection with its $3.8 million purchase of condominium units in an existing building in Allendale, New Jersey (the “Property”) that PCT uses as a laboratory and stem cell processing facility. The First Mortgage is payable in 239 consecutive monthly payments of principal and interest, based on a 20 year amortization schedule; and one final payment of all outstanding principal plus accrued interest then due. The current monthly installment is $20,766, which includes interest at an initial rate of 5.00%; the interest rate and monthly installments payments are subject to adjustment on October 1, 2017. On that date, upon prior written notice, the lender has the option to declare the entire outstanding principal balance, together with all outstanding interest, due and payable in full. The First Mortgage is secured by substantially all of the assets of PCT, including a first mortgage on the Property and assignment of an amount approximately equal to eighteen months debt service held in escrow. The Note matures on October 1, 2027 if not called by the lender on October 1, 2017. The First Mortgage had previously been subject to certain debt service coverage and total debt to tangible net worth financial covenant ratios measured semi-annually. The outstanding balance was approximately $2.4 million and 2.5 million at March 31, 2014 and December 31, 2013, respectively, of which $128,300 is payable within twelve months as of March 31, 2014.
	In December 2010 PCT Allendale, a wholly-owned subsidiary of PCT, entered into a note for a second mortgage in the amount of $1 million (the "Second Mortgage") on the Allendale Property with TD Bank, N.A. The initial guarantors of the Second Mortgage were PCT, DomaniCell (a wholly-owned subsidiary of PCT, now known as NeoStem Family Storage, LLC), Regional Cancer Care Associates LLC and certain of its partners. The Second Mortgage had been subject to an annual financial covenant starting December 31, 2011. The Second Mortgage is for 124 months at a fixed rate of 6% for the first 64 months. The loan is callable for a certain period prior to the interest reset date. The outstanding balance was approximately $0.7 million and $0.8 million at March 31, 2014 and December 31, 2013, respectively, of which $87,700 is payable within twelve months as of March 31, 2014.
	In December 2013, the Company modified both the First Mortgage and Second Mortgage with TD Bank, N.A., whereby (i) prior debt service coverage and total debt to tangible net worth financial covenant ratios were replaced with a minimum unencumbered liquidity covenant, and (ii) prior guarantors were released (see Note 13) and replaced with NeoStem, PCT, and NeoStem Family Storage. The Company is in compliance with the new minimum unencumbered liquidity covenant.

Shareholders_Equity

Shareholders' Equity	3 Months Ended
	Mar. 31, 2014
Shareholdersb Equity [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Shareholders' Equity
	Reverse Stock Split
	On June 28, 2013, pursuant to prior shareholder authorization, the Company’s board of directors unanimously approved a 1-for-10 reverse stock split of the Company’s common stock, which the Company effected on July 16, 2013. All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods to give retroactive effect to the reverse stock split. The shares of common stock retained a par value of $0.001 per share. Accordingly, the stockholders’ deficit reflects the reverse stock split by reclassifying from “common stock” to “Additional paid-in capital” an amount equal to the par value of the decreased shares resulting from the reverse stock split.
	Equity Issuances
	In September 2011, the Company entered into a common stock purchase agreement (the “Initial Purchase Agreement”) with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”), which provided that Aspire Capital was committed to purchase up to an aggregate of $20.0 million worth of shares of the Company’s common stock over the 24-month term. In August, 2012, the Initial Purchase Agreement was extended for an additional 24-month term through September 2015. During the three months ended March 31, 2014, the Company issued 0.8 million shares of Common Stock under the provisions the Initial Purchase Agreement with Aspire for gross proceeds of approximately $5.6 million. As of March 31, 2014, the full $20.0 million worth of shares of the Company's stock had been issued under the Initial Purchase Agreement.
	In March 2014, the Company entered into a new common stock purchase agreement (the “Purchase Agreement”) with Aspire Capital, which provides that, subject to certain terms and conditions, Aspire Capital is committed to purchase up to an aggregate of $30.0 million worth of shares of the Company’s common stock over the 24-month term. At the Company’s discretion, it may present Aspire Capital with purchase notices from time to time to purchase the Company’s common stock, provided certain price and other requirements are met. The purchase price for the shares of stock was based upon one of two formulas set forth in the Purchase Agreement depending on the type of purchase notice the Company submits to Aspire Capital, and is based on market prices of the Company’s common stock (in the case of regular purchases) or a discount of 5% applied to volume weighted average prices (in the case of VWAP purchases), in each case as determined by parameters defined in the Purchase Agreement. As consideration for entering into the Purchase Agreement, we are obligated to issue 150,000 shares of our common stock to Aspire Capital (the “Commitment Shares”).
	Option Exercises
	During the three months ended ended March 31, 2014, option holders exercised an aggregate of 12,800 options at at exercise prices between of $5.20 and $6.20 per share for gross proceeds of approximately $0.1 million.
	Warrant Exercises
	During the three months ended ended March 31, 2014, warrant holders exercised an aggregate of 250,000 warrants at an exercise price of $5.10 per share for gross proceeds of approximately $1.3 million.
	Stock Options and Warrants
	The following table summarizes the activity for stock options and warrants for the three months ended March 31, 2014:
		Stock Options								Warrants
		Shares		Weighted Average Exercise Price			Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
	Outstanding at December 31, 2013	2,932,191		$	11.19		6.8	$	1,658.10	4,898,266		$	16.5	2.6	$	1,811.00
	Changes during the Period:
	Granted	1,169,200		$	7.7					2,722		$	12.26
	Exercised	(12,800	)	$	5.58					(250,000	)	$	5.1
	Forfeited	(109,329	)	$	6.97					(100,108	)	$	70
	Expired	(66,565	)	$	14.77					(59,852	)	$	57.76
	Outstanding at March 31, 2014	3,912,697		$	10.22		7.4	$	1,896.70	4,491,028		$	15.39	2.4	$	1,661.50
	Vested at March 31, 2014 or expected to vest in the future	3,596,457		$	10.46		7.2	$	1,848.90	4,491,028		$	15.39	2.4	$	1,661.50
	Vested at March 31, 2014	2,520,755		$	11.5		6.5	$	1,600.90	4,473,306		$	15.42	2.3	$	1,661.50
	During the three months ended March 31, 2014 and 2013, the Company issued warrants for services as follows ($ in thousands, except share data):
		Three Months Ended March 31,
		2014			2013
	Number of Common Stock Purchase Warrants Issued	—			3,913
	Value of Common Stock Purchase Warrants Issued	$	—		$	14.9
	Restricted Stock
	During the three months ended March 31, 2014 and 2013, the Company issued restricted stock for services as follows ($ in thousands, except share data):
		Three Months Ended March 31,
		2014			2013
	Number of Restricted Stock Issued	329,698			177,492
	Value of Restricted Stock Issued	$	2,511.70		$	1,127.90
	The weighted average estimated fair value of restricted stock issued for services in the three months ended March 31, 2014 and 2013 was $7.62 and $6.35 per share, respectively. The fair value of the restricted stock was determined using the Company’s closing stock price on the date of issuance. The vesting terms of restricted stock issuances are generally within one year.

ShareBased_Compensation_Notes

Share-Based Compensation (Notes)	3 Months Ended
	Mar. 31, 2014
Share-based Compensation [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Share-Based Compensation
	Share-based Compensation
	We utilize share-based compensation in the form of stock options, warrants and restricted stock.  The following table summarizes the components of share-based compensation expense for the three months ended March 31, 2014 and 2013 (in thousands):
			Three Months Ended March 31,
			2014			2013
	Cost of goods sold		$	138.1		$	86.4
	Research and development		476.8			217.4
	Selling, general and administrative		3,278.70			1,914.70
	Total share-based compensation expense		$	3,893.60		$	2,218.50
	Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at March 31, 2014 were as follows (dollars in thousands):
		Stock Options			Warrants			Restricted Stock
	Unrecognized compensation cost	$	6,490.00		$	46.2		$	208.2
	Expected weighted-average period in years of compensation cost to be recognized	5.62			1.3			0.35
	Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March 31, 2014 and 2013 were as follows (dollars in thousands):
		Stock Options						Warrants
		Three Months Ended March 31,						Three Months Ended March 31,
		2014			2013			2014		2013
	Total fair value of shares vested	$	1,927.40		$	1,305.00		$	8.7	$	43.8
	Weighted average estimated fair value of shares granted	$	5.47		$	4.71		$	—	$	3.82

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2014
Income Taxes [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Shareholders' Equity
	Reverse Stock Split
	On June 28, 2013, pursuant to prior shareholder authorization, the Company’s board of directors unanimously approved a 1-for-10 reverse stock split of the Company’s common stock, which the Company effected on July 16, 2013. All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods to give retroactive effect to the reverse stock split. The shares of common stock retained a par value of $0.001 per share. Accordingly, the stockholders’ deficit reflects the reverse stock split by reclassifying from “common stock” to “Additional paid-in capital” an amount equal to the par value of the decreased shares resulting from the reverse stock split.
	Equity Issuances
	In September 2011, the Company entered into a common stock purchase agreement (the “Initial Purchase Agreement”) with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”), which provided that Aspire Capital was committed to purchase up to an aggregate of $20.0 million worth of shares of the Company’s common stock over the 24-month term. In August, 2012, the Initial Purchase Agreement was extended for an additional 24-month term through September 2015. During the three months ended March 31, 2014, the Company issued 0.8 million shares of Common Stock under the provisions the Initial Purchase Agreement with Aspire for gross proceeds of approximately $5.6 million. As of March 31, 2014, the full $20.0 million worth of shares of the Company's stock had been issued under the Initial Purchase Agreement.
	In March 2014, the Company entered into a new common stock purchase agreement (the “Purchase Agreement”) with Aspire Capital, which provides that, subject to certain terms and conditions, Aspire Capital is committed to purchase up to an aggregate of $30.0 million worth of shares of the Company’s common stock over the 24-month term. At the Company’s discretion, it may present Aspire Capital with purchase notices from time to time to purchase the Company’s common stock, provided certain price and other requirements are met. The purchase price for the shares of stock was based upon one of two formulas set forth in the Purchase Agreement depending on the type of purchase notice the Company submits to Aspire Capital, and is based on market prices of the Company’s common stock (in the case of regular purchases) or a discount of 5% applied to volume weighted average prices (in the case of VWAP purchases), in each case as determined by parameters defined in the Purchase Agreement. As consideration for entering into the Purchase Agreement, we are obligated to issue 150,000 shares of our common stock to Aspire Capital (the “Commitment Shares”).
	Option Exercises
	During the three months ended ended March 31, 2014, option holders exercised an aggregate of 12,800 options at at exercise prices between of $5.20 and $6.20 per share for gross proceeds of approximately $0.1 million.
	Warrant Exercises
	During the three months ended ended March 31, 2014, warrant holders exercised an aggregate of 250,000 warrants at an exercise price of $5.10 per share for gross proceeds of approximately $1.3 million.
	Stock Options and Warrants
	The following table summarizes the activity for stock options and warrants for the three months ended March 31, 2014:
		Stock Options								Warrants
		Shares		Weighted Average Exercise Price			Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
	Outstanding at December 31, 2013	2,932,191		$	11.19		6.8	$	1,658.10	4,898,266		$	16.5	2.6	$	1,811.00
	Changes during the Period:
	Granted	1,169,200		$	7.7					2,722		$	12.26
	Exercised	(12,800	)	$	5.58					(250,000	)	$	5.1
	Forfeited	(109,329	)	$	6.97					(100,108	)	$	70
	Expired	(66,565	)	$	14.77					(59,852	)	$	57.76
	Outstanding at March 31, 2014	3,912,697		$	10.22		7.4	$	1,896.70	4,491,028		$	15.39	2.4	$	1,661.50
	Vested at March 31, 2014 or expected to vest in the future	3,596,457		$	10.46		7.2	$	1,848.90	4,491,028		$	15.39	2.4	$	1,661.50
	Vested at March 31, 2014	2,520,755		$	11.5		6.5	$	1,600.90	4,473,306		$	15.42	2.3	$	1,661.50
	During the three months ended March 31, 2014 and 2013, the Company issued warrants for services as follows ($ in thousands, except share data):
		Three Months Ended March 31,
		2014			2013
	Number of Common Stock Purchase Warrants Issued	—			3,913
	Value of Common Stock Purchase Warrants Issued	$	—		$	14.9
	Restricted Stock
	During the three months ended March 31, 2014 and 2013, the Company issued restricted stock for services as follows ($ in thousands, except share data):
		Three Months Ended March 31,
		2014			2013
	Number of Restricted Stock Issued	329,698			177,492
	Value of Restricted Stock Issued	$	2,511.70		$	1,127.90
	The weighted average estimated fair value of restricted stock issued for services in the three months ended March 31, 2014 and 2013 was $7.62 and $6.35 per share, respectively. The fair value of the restricted stock was determined using the Company’s closing stock price on the date of issuance. The vesting terms of restricted stock issuances are generally within one year.
Income Tax Disclosure [Text Block]	'
	Income Taxes
	As of December 31, 2013, the Company had approximately $110.6 million of Federal NOLs available to offset future taxable income expiring from 2025 through 2033. In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s NOLs could be limited in the event of a change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible.  If a change of ownership did occur there would be an annual limitation on the usage of the Company’s losses which are available through 2033.
	In assessing the realizability of deferred tax assets, including the net operating loss carryforwards ("NOLs"), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.
	Deferred tax liabilities were $4.4 million and $4.4 million as of March 31, 2014 and December 31, 2013, and relate to the taxable temporary differences on the goodwill recognized in the PCT acquisition in 2011, and the in-process R&D intangible asset recognized in the Amorcyte acquisition in 2011. The taxable temporary difference associated with the goodwill, which is tax deductible and will be amortized over 15 years, will continue to increase the deferred tax liability balance over the amortization period, with an associated charge to the tax provision in each period. The deferred tax liabilities will only reverse when these indefinite-lived assets are sold, impaired, or reclassified from an indefinite-lived asset to a finite-lived asset.
	As of March 31, 2014, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions [Text Block]	'
	Related Party Transactions
	In December 2013, the Company modified both the First Mortgage and Second Mortgage with TD Bank, N.A. (see Note 9). Pursuant to the Loan Modifications, Andrew L. Pecora, M.D., Regional Cancer Care Associates LLC (Dr. Pecora’s medical practice), and certain partners in such practice, have been released as guarantors of the Second Mortgage Loan, and NeoStem has become a guarantor of the Loans pursuant to a Guaranty of Payment delivered by NeoStem to the Lender. Dr. Pecora, currently serves as a NeoStem director, NeoStem’s Chief Visionary Officer, PCT’s Chief Medical Officer and Amorcyte’s Chief Scientific Officer.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies [Abstract]	'
Commitments and Contingencies [Text Block]	'
	Commitments and Contingencies
	Lease Commitments
	The Company leases offices, of which certain have escalation clauses and renewal options, and also leases equipment under certain noncancelable operating leases that expire from time to time through 2018. In January 2014, the Company signed a new lease for additional space at its current executive offices at 420 Lexington Avenue, New York, NY 10170. The new lease is believed to provide sufficient space for the near future and shall extend through 2018. This property is used as the Company's corporate headquarters.
	A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of March 31, 2014 are as follows (in thousands):
	Years ended	Operating Leases
	2014	$	763
	2015	840.4
	2016	682.3
	2017	386.9
	2018	5.9
	Total minimum lease payments	$	2,678.50
	Expense incurred under operating leases was approximately $0.2 million and $0.3 million for the three months ended March 31, 2014 and 2013, respectively.
	Contingencies
	Under license agreements with third parties the Company is typically required to pay maintenance fees, make milestone payments and/or pay other fees and expenses and pay royalties upon commercialization of products. The Company also sponsors research at various academic institutions, which research agreements generally provide us with an option to license new technology discovered during the course of the sponsored research.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Subsequent Events
	California Stem Cell Acquisition
	On May 8, 2014 (the “Closing”), NeoStem closed its acquisition (the “CSC Acquisition”) of CSC, pursuant to the terms of the Agreement and Plan of Merger, dated as of April 11, 2014 (the “Merger Agreement”), by and among NeoStem, CSC, NBS Acquisition Sub I, Inc., a Delaware corporation and a wholly-owned subsidiary of NeoStem (“Subco”), NBS Acquisition Sub II, LLC, a Delaware limited liability company and a wholly-owned subsidiary of NeoStem (“Subco II”), and Jason Livingston, solely in his capacity as CSC stockholder representative (together with his permitted successors, the “CSC Representative”).
	Pursuant to the Merger Agreement, on the Closing Date, (1) Subco was merged with and into CSC (the “First Merger”) and (2) CSC was then merged with and into Subco II (the “Second Merger”, and collectively with the First Merger, the “Mergers”), with Subco II surviving the Mergers as a wholly-owned subsidiary of NeoStem. At Closing, Subco II changed its legal name to NeoStem Oncology, LLC.
	CSC (which after the Mergers is known as NeoStem Oncology, LLC) is a biopharmaceutical company with deep expertise in stem cell biology that is engaged in the development of therapies using a patient’s own, i.e., autologous, cells. To date, CSC’s development efforts have been directed at immunotherapies for cancer, regenerative medicine for motor neuron replacement and dermatology. CSC’s most advanced program is an immunotherapy, Melapuldencel-T, which uses patients’ own tumor cells to maximize the ability of their immune system to identify and eliminate the cancer initiating cells that are capable of reconstituting or developing new tumors (i.e., “cancer stem cells” or “replicating cells”). The focus of that program is the treatment of metastatic melanoma. As a result of encouraging Phase 2 data, CSC expects to initiate a Phase 3 clinical trial later in 2014, for which it has received Special Protocol Assessment (“SPA”) and Fast Track designation, as well as Orphan Drug designation. CSC maintains corporate offices and research facilities in Irvine, California.
	Aggregate Merger Consideration
	Pursuant to the terms of the Merger Agreement, all shares of CSC common stock (“CSC Common Stock”) and CSC preferred stock (“CSC Preferred Stock”, and collectively with the CSC Common Stock, the “CSC Capital Stock”) outstanding immediately prior to the Closing, and all outstanding unexercised options to purchase CSC Common Stock (“CSC Options”) (treated as if a net exercise had occurred), were canceled and converted into the right to receive, in the aggregate (and giving effect to the liquidation preferences accorded to the CSC Preferred Stock):
	-1	An aggregate of 5,329,593 shares of NeoStem common stock (subject to payment of cash in lieu of fractional shares) (the “Closing Merger Consideration”).
	-2	If payable after the Closing, certain milestone payments in an amount of up to $90 million in the aggregate, payable in shares of NeoStem common stock or cash, in NeoStem’s sole discretion, in the event of the successful completion of certain milestone events in connection with the CSC business acquired by NeoStem (the “Milestone Payments”, and together with the Closing Merger Consideration, the “Merger Consideration”).

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Summary of Significant Accounting Policies [Abstract]	'
Receivables, Policy [Policy Text Block]	'
	Accounts Receivable
	Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. The Company applies judgment in connection with establishing the allowance for doubtful accounts. Specifically, the Company analyzes the aging of accounts receivable balances, historical bad debts, customer concentration and credit-worthiness, current economic trends and changes in the Company’s customer payment terms. Significant changes in customer concentrations or payment terms, deterioration of customer credit-worthiness or weakening economic trends could have a significant impact on the collectability of the receivables and the Company’s operating results. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. Management regularly reviews the aging of receivables and changes in payment trends by its customers, and records a reserve when it believes collection of amounts due are at risk.
Goodwill and Intangible Assets, Policy [Policy Text Block]	'
	Goodwill and Other Intangible Assets
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	Clinical Services: The Company recognizes revenue for its (i) process development and (ii) clinical manufacturing services based on the terms of individual contracts.
	Revenues associated with process development services generally contain multiple stages that do not have stand-alone values and are dependent upon one another, and are recognized as revenue on a completed contract basis. We recognize revenues when all of the following conditions are met:
	•	persuasive evidence of an arrangement exists;
	•	delivery has occurred or the services have been rendered;
	•	the fee is fixed or determinable; and
	•	collectability is probable.
	The Company considers signed contracts as evidence of an arrangement. The Company assesses whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the payment terms are subject to refund or adjustment. The Company assesses cash collectability based on a number of factors, including past collection history with the client and the client's creditworthiness. If the Company determines that collectability is not reasonably assured, it defers revenue recognition until collectability becomes reasonably assured, which is generally upon receipt of the cash. The Company's arrangements are generally non-cancellable, though clients typically have the right to terminate their agreement for cause if the Company materially fails to perform.
	Clinical manufacturing services are generally distinct arrangements whereby the Company is paid for time and materials or for fixed monthly amounts. Revenue is recognized when efforts are expended or contractual terms have been met.
	Some client agreements include multiple elements, comprised of process development and clinical manufacturing services. The Company believes that process development and clinical manufacturing services each have stand-alone value because these services can be provided separately by other companies. In accordance with ASC Update No. 2009-13, “Revenue Recognition (Topic 605): Multiple-Deliverable Revenue Arrangements,” the Company (1) separates deliverables into separate units of accounting when deliverables are sold in a bundled arrangement and (2) allocates the arrangement's consideration to each unit in the arrangement based on its relative selling price.
	Clinical Services Reimbursements: The Company separately charges the customers for the expenses associated with certain consumable resources (reimbursable expenses) that are specified in each clinical services contract. On a monthly basis, the Company bills customers for reimbursable expenses and immediately recognizes these billings as revenue, as the revenue is deemed earned as reimbursable expenses are incurred. For the three months ended March 31, 2014 and 2013, clinical services reimbursements were $0.7 million and $0.4 million, respectively.
	Processing and Storage Services: The Company recognizes revenue related to the collection and cryopreservation of cord blood and autologous adult stem cells when the cryopreservation process is completed which is approximately twenty-four hours after cells have been collected. Revenue related to advance payments of storage fees is recognized ratably over the period covered by the advance payments.

The_Business_Tables

The Business (Tables)	3 Months Ended
	Mar. 31, 2014
The Business [Abstract]	'
Subsidiary [Table Text Block]	'
	.
	Entity	Percentage of Ownership	Location
	NeoStem, Inc.	Parent  Company	United States of America
	NeoStem Therapies, Inc.	100%	United States of America
	Stem Cell Technologies, Inc.	100%	United States of America
	Amorcyte, LLC	100%	United States of America
	Progenitor Cell Therapy, LLC (PCT)	100%	United States of America
	NeoStem Family Storage, LLC	100%	United States of America
	Athelos Corporation (1)	90%	United States of America
	PCT Allendale, LLC	100%	United States of America
	NeoStem Oncology, LLC (2)	100%	United States of America

Loss_Per_Share_Tables

Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2014
Loss Per Share [Abstract]	'
ScheduleOfDilutiveSecuritiesExcludedFromComputationOfEarningsPerShare [Table Text Block]	'
	At March 31, 2014 and 2013, the Company excluded the following potentially dilutive securities:
		March 31,
		2014	2013
	Stock Options	3,912,697	2,631,181
	Warrants	4,491,028	5,501,055
	Restricted Shares	175,731	35,500

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Measurements [Abstract]	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
	For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the three months ended March 31, 2014 by type of instrument (in thousands):
			Three Months Ended
			March 31, 2014
			Warrants			Acquisition-Related Contingent Consideration
	Beginning liability balance		$	23.2		$	9,450.00
	Change in fair value recorded in earnings		—			190
	Ending liability balance		$	23.2		$	9,640.00
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis, Valuation Techniques [Table Text Block]	'
	The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2014, and December 31, 2013 (in thousands):
		March 31, 2014
		Fair Value Measurements Using Fair Value Hierarchy
		Level 1			Level 2			Level 3
	Warrant derivative liabilities	$	—		$	—		$	23.2
	Acquisition-related contingent consideration	—			—			9,640.00

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2014
Goodwill and Other Intangible Assets [Abstract]	'
Schedule of Finite-Lived Intangible Assets by Major Class [Table Text Block]	'
	The Company's intangible assets and related accumulated amortization as of March 31, 2014 and December 31, 2013 consisted of the following (in thousands):
				31-Mar-14								31-Dec-13
		Useful Life		Gross			Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
	Customer list	10 years		$	1,000.00		$	(320.1	)	$	679.9	$	1,000.00	$	(295.1	)	$	704.9
	Manufacturing technology	10 years		3,900.00			(1,248.4		)	2,651.60		3,900.00		(1,150.9		)	2,749.10
	Tradename	10 years		800			(256.1		)	543.9		800		(236.1		)	563.9
	In process R&D	Indefinite		9,400.00			—			9,400.00		9,400.00		—			9,400.00
	VSEL patent rights	19 years		669			(220.1		)	448.9		669		(211.3		)	457.7
	Total Intangible Assets			$	15,769.00		$	(2,044.7	)	$	13,724.30	$	15,769.00	$	(1,893.4	)	$	13,875.60
Schedule of Amortization Expense [Table Text Block]	'
	Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):
			Three Months Ended March 31,
			2014			2013
	Cost of revenue		$	79.2		$	97.5
	Research and development		27.1			8.8
	Selling, general and administrative		45			45
	Total		$	151.3		$	151.3
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	Estimated intangible amortization expense on an annual basis for the succeeding five years is as follow (in thousands):
	2014	$	453.9
	2015	605.2
	2016	605.2
	2017	605.2
	2018	605.2
	Thereafter	10,849.60
		$	13,724.30

Accrued_Liabilities_Accrued_Li

Accrued Liabilities Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2014
Accrued Liabilities [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	Accrued liabilities as of March 31, 2014 and December 31, 2013 were as follows (in thousands):
		March 31, 2014		31-Dec-13
	Salaries, employee benefits and related taxes	$	846.4	$	2,325.80
	Professional fees	775.4		544.8
	License Fees	200		500
	Other	559.8		647.4
		$	2,381.60	$	4,018.00

Shareholders_Equity_Tables

Shareholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2014
Shareholdersb Equity [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table summarizes the activity for stock options and warrants for the three months ended March 31, 2014:
		Stock Options								Warrants
		Shares		Weighted Average Exercise Price			Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
	Outstanding at December 31, 2013	2,932,191		$	11.19		6.8	$	1,658.10	4,898,266		$	16.5	2.6	$	1,811.00
	Changes during the Period:
	Granted	1,169,200		$	7.7					2,722		$	12.26
	Exercised	(12,800	)	$	5.58					(250,000	)	$	5.1
	Forfeited	(109,329	)	$	6.97					(100,108	)	$	70
	Expired	(66,565	)	$	14.77					(59,852	)	$	57.76
	Outstanding at March 31, 2014	3,912,697		$	10.22		7.4	$	1,896.70	4,491,028		$	15.39	2.4	$	1,661.50
	Vested at March 31, 2014 or expected to vest in the future	3,596,457		$	10.46		7.2	$	1,848.90	4,491,028		$	15.39	2.4	$	1,661.50
	Vested at March 31, 2014	2,520,755		$	11.5		6.5	$	1,600.90	4,473,306		$	15.42	2.3	$	1,661.50
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
	During the three months ended March 31, 2014 and 2013, the Company issued warrants for services as follows ($ in thousands, except share data):
		Three Months Ended March 31,
		2014			2013
	Number of Common Stock Purchase Warrants Issued	—			3,913
	Value of Common Stock Purchase Warrants Issued	$	—		$	14.9
Restricted Stock [Table Text Block]	'
	During the three months ended March 31, 2014 and 2013, the Company issued restricted stock for services as follows ($ in thousands, except share data):
		Three Months Ended March 31,
		2014			2013
	Number of Restricted Stock Issued	329,698			177,492
	Value of Restricted Stock Issued	$	2,511.70		$	1,127.90

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2014
Share-based Compensation [Abstract]	'
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
	The following table summarizes the components of share-based compensation expense for the three months ended March 31, 2014 and 2013 (in thousands):
			Three Months Ended March 31,
			2014			2013
	Cost of goods sold		$	138.1		$	86.4
	Research and development		476.8			217.4
	Selling, general and administrative		3,278.70			1,914.70
	Total share-based compensation expense		$	3,893.60		$	2,218.50
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	'
	Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at March 31, 2014 were as follows (dollars in thousands):
		Stock Options			Warrants			Restricted Stock
	Unrecognized compensation cost	$	6,490.00		$	46.2		$	208.2
	Expected weighted-average period in years of compensation cost to be recognized	5.62			1.3			0.35
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]	'
	Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March 31, 2014 and 2013 were as follows (dollars in thousands):
		Stock Options						Warrants
		Three Months Ended March 31,						Three Months Ended March 31,
		2014			2013			2014		2013
	Total fair value of shares vested	$	1,927.40		$	1,305.00		$	8.7	$	43.8
	Weighted average estimated fair value of shares granted	$	5.47		$	4.71		$	—	$	3.82

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of March 31, 2014 are as follows (in thousands):
	Years ended	Operating Leases
	2014	$	763
	2015	840.4
	2016	682.3
	2017	386.9
	2018	5.9
	Total minimum lease payments	$	2,678.50

The_Business_Details

The Business (Details) (USD $)	0 Months Ended		3 Months Ended
	Jun. 18, 2012	Jun. 19, 2012	Mar. 31, 2014
	segment	segment
The Company [Line Items]	'	'	'
Change in Ownership in Subsidiary	'	'	$0
Number of Reporting Segments	3	1	'
Noncontrolling Interest [Member]	'	'	'
The Company [Line Items]	'	'	'
Change in Ownership in Subsidiary	'	'	$86,617

The_Business_Principal_of_cons

The Business Principal of consolidation (Details)	3 Months Ended
	Mar. 31, 2014
NeoStem, Inc. [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Minority Interest Ownership Percentage By Parent [String]	'ParentB Company
NeoStem Therapies, Inc [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Subsidiary, Ownership Interest by Parent	100.00%
Stem Cell Technologies, Inc [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Subsidiary, Ownership Interest by Parent	100.00%
Amorcyte, LLC [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Subsidiary, Ownership Interest by Parent	100.00%
China Biopharmaceuticals Holdings, Inc. [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest	100.00%
Suzhou Erye Pharmaceuticals Company Ltd. [Member] | CHINA	'
Schedule of Subisidiary [Line Items]	'
Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest	51.00%
Progenitor Cell Therapy, LLC [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Subsidiary, Ownership Interest by Parent	100.00%
NeoStem Family Storage, LLC [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest	100.00%
Minority Interest Ownership Percentage By Parent [String]	'1
Athelos Corporation [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest	90.00%
Minority Interest Ownership Percentage By Parent [String]	'0.90
PCT Allendale, LLC [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest	100.00%
Minority Interest Ownership Percentage By Parent [String]	'1

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Summary of Significant Accounting Policies [Abstract]	'	'
Clinical Services Reimbursement	$0.70	$0.40

Cash_and_Cash_Equivalents_Deta

Cash and Cash Equivalents (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Cash and Cash Equivalents [Abstract]	'	'
Cash and cash equivalents	$41,359,652	$46,133,759
Cash, FDIC Insured Amount	$700,000	$800,000

Inventories_Details

Inventories (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Schedule of Inventory [Line Items]	'	'
Inventory	$1,475,812	$1,270,223
Multiple Stage Contracts [Member]	'	'
Schedule of Inventory [Line Items]	'	'
Deferred Revenue	$1,600,000	$1,500,000

Loss_Per_Share_Details

Loss Per Share (Details)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Warrants	'	'
Class of Stock [Line Items]	'	'
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	4,491,028	5,501,055
Stock Options [Member]	'	'
Class of Stock [Line Items]	'	'
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	3,912,697	2,631,181
Restricted Stock [Member]	'	'
Class of Stock [Line Items]	'	'
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	175,731	35,500

Fair_Value_Measurements_Fair_v

Fair Value Measurements Fair value hierarchy the Companybs financial assets and liabilities (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Business Combination, Contingent Consideration, Liability	$9,640,000	$9,450,000
Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant Derivative Liabilities	0	0
Contingent Consideration Classified As Equity Fair Value Disclosure	0	0
Fair Value, Inputs, Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant Derivative Liabilities	0	0
Contingent Consideration Classified As Equity Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant Derivative Liabilities	23,200	23,200
Contingent Consideration Classified As Equity Fair Value Disclosure	$9,640,000	$9,450,000

Fair_Value_Measurements_Financ

Fair Value Measurements Financial instruments with significant Level 3 inputs (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
Warrants	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'
Beginning liability balance	$23,200
Change in fair value recorded in earnings	0
Ending liability balance	23,200
contingent cosideration [Member]	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'
Beginning liability balance	9,450,000
Change in fair value recorded in earnings	190,000
Ending liability balance	$9,640,000

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets Intangible Assets and Related Accumulated Amortization (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	$15,769,000	$15,769,000
Finite-Lived Intangible Assets, Accumulated Amortization	-2,044,700	-1,893,400
Finite-Lived Intangible Assets, Net	13,724,300	13,875,600
Customer Lists [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	1,000,000	1,000,000
Finite-Lived Intangible Assets, Accumulated Amortization	-320,100	-295,100
Finite-Lived Intangible Assets, Net	679,900	704,900
Finite-Lived Intangible Assets, Useful Life	'10 years	'
Manufacturing Technology [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	3,900,000	3,900,000
Finite-Lived Intangible Assets, Accumulated Amortization	-1,248,400	-1,150,900
Finite-Lived Intangible Assets, Net	2,651,600	2,749,100
Finite-Lived Intangible Assets, Useful Life	'10 years	'
Trade Names [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	800,000	800,000
Finite-Lived Intangible Assets, Accumulated Amortization	-256,100	-236,100
Finite-Lived Intangible Assets, Net	543,900	563,900
Finite-Lived Intangible Assets, Useful Life	'10 years	'
In Process R and D [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	9,400,000	9,400,000
Finite-Lived Intangible Assets, Accumulated Amortization	0	0
Finite-Lived Intangible Assets, Net	9,400,000	9,400,000
Finite Lived Intangible Assets, Useful Life [String]	'Indefinite	'
VSEL Patent Rights [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	669,000	669,000
Finite-Lived Intangible Assets, Accumulated Amortization	-220,100	-211,300
Finite-Lived Intangible Assets, Net	$448,900	$457,700
Finite-Lived Intangible Assets, Useful Life	'19 years	'

Goodwill_and_Other_Intangible_3

Goodwill and Other Intangible Assets Intangible Amortization Expense (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization of Intangible Assets	$151,300	$151,300
Cost of revenue	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization of Intangible Assets	79,200	97,500
Research and development	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization of Intangible Assets	27,100	8,800
Selling, general and administrative	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization of Intangible Assets	$45,000	$45,000

Goodwill_and_Other_Intangible_4

Goodwill and Other Intangible Assets Goodwill (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Goodwill [Abstract]	'	'
Goodwill	$11,117,770	$11,117,770
Future Amortization Expense, Year One	453,900	'
Future Amortization Expense, Year Two	605,200	'
Future Amortization Expense, Year Three	605,200	'
Future Amortization Expense, Year Four	605,200	'
Finite-Lived Intangible Assets, Amortization Expense, Year Five	605,200	'
Thereafter	10,849,600	'
Finite-Lived Intangible Assets, Future Amortization Expense	$13,724,300	$13,875,600

Accrued_Liabilities_Accrued_Li1

Accrued Liabilities Accrued Liabilities (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Accrued Liabilities [Abstract]	'	'
Salaries, employee benefits and related taxes	$846.40	$2,325.80
Professional fees	775.4	544.8
Accrued Royalties, Current	200	500
Other	559.8	647.4
Accrued Liabilities	$2,381.60	$4,018

Debt_Details

Debt (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Oct. 31, 2007	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Dec. 06, 2010	Mar. 31, 2014	Dec. 31, 2013
			Convertible Notes Payable [Member]	Convertible Notes Payable [Member]	Convertible Notes Payable [Member]	PCT Allendale, LLC [Member]	PCT Allendale, LLC [Member]	PCT Allendale, LLC [Member]	PCT Allendale, LLC [Member]
							Convertible Notes Payable [Member]	Convertible Notes Payable [Member]	Convertible Notes Payable [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'
Notes Payable	$1,700,000	$900,000	'	'	'	'	'	'	'
Purchase of condominium units	'	'	0	'	'	'	'	'	'
Debt Instrument, Frequency of Periodic Payment	'	'	'monthly payments	'	'	'	'	'	'
Debt Instrument, Periodic Payment	'	'	'	'	'	20,766	'	'	'
Debt Instrument, Periodic Payment, Interest	'	'	'	5.00%	'	'	6.00%	'	'
Mortgage Loans on Real Estate, Carrying Amount of Mortgages	'	'	'	2,400,000	2,500,000	'	'	741,800	763,000
Mortgage Loan Repayble Amount within 12 months	'	'	'	'	'	128,300	'	87,700	'
Mortgage Loans on Real Estate, New Mortgage Loans	'	'	$3.10	'	'	'	$1,000,000	'	'
Debt Instrument, Period of Loan	'	'	'	'	'	'	'124 months	'	'
Debt Instrument, Period of Fixed Interest Rate	'	'	'	'	'	'	'64 months	'	'

Preferred_Stock_Convertible_Re

Preferred Stock Convertible Redeemable Series E Preferred Stock (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Class of Stock [Line Items]	'	'	'
Preferred stock, par value	$0.01	'	$0.01
Net proceeds from issuance of common stock	$5,630,625	$2,730,262	'
Preferred Stock, Shares Outstanding	10,000	'	10,000
Fair Value, Inputs, Level 3 [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Warrant Derivative Liabilities	$23,200	'	$23,200

Shareholders_Equity_Equity_Iss

Shareholders' Equity Equity Issuances (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2012	Mar. 31, 2014	Sep. 28, 2011	Mar. 31, 2014	Mar. 31, 2014
In Millions, except Share data, unless otherwise specified			Private Placement [Member]	Aspire Capital Purchase Agreement [Member]	Aspire Capital Purchase Agreement [Member]	Aegis Capital Purchase Agreement [Member]	Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]	'	'	'	'	'	'	'
Committment Value Under Purchase Agreement	'	'	'	'	$20	'	'
Term Of Agreement In Months	'	'	'	'	24	'	'
Discount Applied To Weighted Average Price	'	'	'	5.00%	'	'	'
Investment Warrants, Exercise Price	'	'	$5.10	'	'	'	'
Shares, Issued	'	'	'	'	'	800,000	'
Proceeds from Issuance of Common Stock Gross	'	'	'	'	'	5.6	'
Common Stock, Shares, Issued	28,593,410	27,196,537	'	'	'	'	150,000
Purchase Commitment, Remaining Minimum Amount Committed	'	'	'	'	'	'	$30

Shareholders_Equity_Warrant_Ex

Shareholders' Equity Warrant Exercises (Details) (USD $)	0 Months Ended	3 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2012	Mar. 31, 2014
	Private Placement [Member]	Warrant holder A [Member]
Stock Options and Warrants [Line Items]	'	'
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	'	250,000
Investment Warrants, Exercise Price	$5.10	'
Proceeds from Issuance of Warrants	'	$1.30

Shareholders_Equity_Stock_opti

Shareholders' Equity Stock options and warrants (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Stock Options and Warrants [Line Items]	'	'	'
Stock Option Exercise	12,800	'	'
Stock Issued During Period, Shares, Other	0	3,913	'
Warrants Issued During Period, Value	$0	$14,900	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	1,896,700	'	'
Common Stock Warrants, Shares	4,491,028	'	4,898,266
Weighted Average Exercise Price, Warrants Outstanding	15.39	'	16.5
Weighted Average Remaining Contractual Term warrant outstanding	'2 years 4 months 24 days	'	'
Aggregate Intrinsic Value, Warrants Outstanding	1,661,500	'	'
Warrants Granted	2,722	'	'
Weighted Average Exercise Price, Warrants Granted	$12.26	'	'
Warrants Exercised	-250,000	'	'
Weighted Average Exercise Price, Warrants Exercised	$5.10	'	'
Warrants Expired	-100,108	'	'
Weighted Average Exercise Price, Warrants Expired	$70	'	'
Warrants Canceled	-59,852	'	'
Weighted Average Exercise Price, Warrants Canceled	$57.76	'	'
Proceeds from Stock Options Exercised	100,000	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value	1,848,900	'	'
shares, vested and expected to vest	4,491,028	'	'
Weighted Average Exercise Price, Warrants vested & expected to vest	15.39	'	'
Aggregate Intrinsic Value, Warrants vested and expected to vest	1,661,500	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	1,600,900	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	4,473,306	'	'
Weighted Average Exercise Price, Warrants Exercisable	15.42	'	'
weighted Average Remaining Contractual Term, warrants vested	'2 years 3 months 18 days	'	'
Aggregate Intrinsic Value, Warrants vested	$1,661,500	'	'
Warrants	'	'	'
Stock Options and Warrants [Line Items]	'	'	'
Weighted average estimated fair value of shares granted	$0	'	$3.82
US Equity Plan [Member]	'	'	'
Stock Options and Warrants [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	3,912,697	'	2,932,191
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$10.22	'	$11.19
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	'7 years 4 months 21 days	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	1,169,200	'	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$7.70	'	'
Stock Options Exercised	-12,800	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$5.58	'	'
Stock Options Expired	-109,329	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price	$6.97	'	'
Stock Options Forfeited	-66,565	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price	$14.77	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	3,596,457	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$10.46	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	'7 years 2 months 9 days	'	'
Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest	'2 years 4 months 24 days	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	2,520,755	'	'
Weighted average estimated fair value of shares granted	$11.50	'	'
Options, Vested, weighted Average Remaining Contractual Term	'6 years 5 months 27 days	'	'
Minimum [Member]	'	'	'
Stock Options and Warrants [Line Items]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$5.20	'	'
Maximum [Member]	'	'	'
Stock Options and Warrants [Line Items]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$6.20	'	'

Shareholders_Equity_Restricted

Shareholders' Equity Restricted Stock (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock Issued During Period, Shares, Restricted Stock Award, Gross	329,698	177,492
Stock Issued During Period, Value, Restricted Stock Award, Gross	$2,511,700	$1,127,900
weighted average estimated fair value of restricted stock	$7.62	$6.35

ShareBased_Compensation_ShareB

Share-Based Compensation Share-Based Compensation (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Allocated Share-based Compensation Expense	$3,893,600	$2,218,500	'
Stock Option [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Unrecognized compensation cost	6,490,000	'	'
Expected weighted-average period in years of compensation cost to be recognized	'5 years 7 months 13 days	'	'
Warrants	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Unrecognized compensation cost	46,200	'	'
Expected weighted-average period in years of compensation cost to be recognized	'1 year 3 months 18 days	'	'
Total fair value of shares vested	8,700	43,800	'
Weighted average estimated fair value of shares granted	$0	'	$3.82
Stock Options [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Weighted average estimated fair value of shares granted	$5.47	'	$4.71
Restricted Stock [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Unrecognized compensation cost	208,200	'	'
Expected weighted-average period in years of compensation cost to be recognized	'4 months 6 days	'	'
Cost of revenue	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Allocated Share-based Compensation Expense	138,100	86,400	'
Research and development	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Allocated Share-based Compensation Expense	476,800	217,400	'
Selling, general and administrative	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Allocated Share-based Compensation Expense	3,278,700	1,914,700	'
Stock Option [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Total fair value of shares vested	$1,927,400	$1,305,000	'

Income_Taxes_Net_Operating_Los

Income Taxes Net Operating Loss Carry Forward (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Operating Loss Carryforwards [Line Items]	'	'
Operating Loss Carryforwards	'	$110,600,000
Deferred Tax Liabilities, Net, Noncurrent	$4,426,635	$4,379,226

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Operating Leases, Future Minimum Payments Due [Abstract]	'	'
2013	$763,000	'
2014	840,400	'
2015	682,300	'
2016	386,900	'
Thereafter	5,900	'
Total minimum lease payments	2,678,500	'
Operating Leases, Rent Expense	$200,000	$300,000

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Subsequent Event [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	4,473,306	'	'
Common Stock, Par Value	$0.00	'	$0.00
Common Stock, Shares, Issued	28,593,410	'	27,196,537
Proceeds from exercise of warrants	$1,275,000	$105,881	'
Proceeds from Stock Options Exercised	71,360	0	'
Aegis Capital Purchase Agreement [Member]	'	'	'
Subsequent Event [Line Items]	'	'	'
Shares, Issued	800,000	'	'
Proceeds from Issuance of Common Stock Gross	$5,600,000	'	'